shine-logo

Katrina Pitas

Home » Katrina Pitas

SHINE breaks ground on HQ and Therapeutics production facility

SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000-square-foot facility that will house its corporate headquarters and a large-scale production facility for the Therapeutics division it established last year.

2022-09-08T09:13:45-05:00December 16, 2020|Safer, Healthier, Cleaner, News, News Releases, Therapeutics, 2020|

SHINE announces first sales of n.c.a. Lu-177

SHINE announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lutetium-177, or Lu-177, is a therapeutic isotope in demand by clinical trial sponsors because of its potential to revolutionize the treatment of cancer patients.

2022-09-08T09:15:17-05:00November 4, 2020|Healthier, News, News Releases, Medical Isotopes, Therapeutics, 2020|

SHINE & IOCB deliver Lu-177 doses to GE

SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient doses of the therapeutic isotope lutetium-177 (Lu-177).

2022-09-08T09:15:03-05:00January 21, 2020|Healthier, News, News Releases, Medical Isotopes, Therapeutics, 2020|

SHINE Creates Therapeutics Division

SHINE Medical Technologies today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise.

2021-12-17T17:41:45-06:00October 11, 2019|News Releases, Archived, Medical Isotopes, 2019|

SHINE Licenses Lu-177 Separation Process

SHINE Medical Technologies and Institute of Organic Chemistry and Biochemistry of the CAS have entered into an intellectual property license agreement providing SHINE with a global, exclusive license to a novel method for separating rare earth elements.  SHINE will use the innovation to produce lutetium-177 (Lu-177) for the treatment of cancer.

2021-12-17T17:45:41-06:00May 15, 2019|News Releases, Archived, Medical Isotopes, 2019|

Grand Opening of new SHINE Global HQ

January 16, 2017 - SHINE Medical Technologies, Inc. (SHINE), a company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, held a ribbon cutting ceremony to celebrate the grand opening of the company’s new global headquarters in downtown Janesville, Wisconsin. The ribbon cutting was led by the John Beckord and the Forward Janesville Goodwill Ambassadors.

2021-12-17T18:52:45-06:00January 16, 2017|News, News Releases, Archived, 2017|

SHINE to Present at Mo-99 Topical Meeting

September 6, 2016 - SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that the company has been invited to speak at the 2016 Mo-99 Topical Meeting hosted by the Department of Energy’s National Nuclear Security Administration (DOE/NNSA).

2021-12-17T18:54:23-06:00September 6, 2016|News Releases, Archived, Medical Isotopes|
Go to Top